Proxima Therapeutics Receives FDA Clearance For Next Generation MammoSite Device; State-Of-The-Art Catheters Will More Comfortably Deliver Targeted Internal Five-Day Radiation Therapy
10/19/2005 5:11:36 PM
Proxima Therapeutics, Inc. today announced that it has received marketing clearance from the United States Food and Drug Administration (FDA) for the next generation of its MammoSite balloon catheter device. The latest version of the MammoSite device incorporates a number of enhanced design features. These include a thinner catheter shaft and a smaller balloon profile that will provide an even less-invasive means of delivering partial breast irradiation to women with early stage breast cancer.
comments powered by